期刊文献+

蛋白酶体抑制剂PS-341对白血病细胞株SHI-1的生长抑制作用研究

Inhibiting effect of proteasome inhibitor PS-341 on leukemic SHI-1 cells in vitro
下载PDF
导出
摘要 目的探讨蛋白酶体抑制剂PS-341对膜连蛋白急性单核细胞白血病细胞株SHI-1的抑制作用。方法台盼蓝拒染法观察不同浓度PS-341对SHI-1细胞活力的影响,用异硫氰酸荧光黄(Annexin-V-FITC)、碘化丙啶(PI)检测60nmol/L浓度PS-341处理0、6、12、24h时的SHI-1细胞凋亡率,并用流式细胞仪检测细胞周期。结果PS-341呈时间和剂量依赖性抑制SHI-1细胞活力;60nmol/L浓度PS-341在0、6、12、24h诱导SHI-1细胞凋亡率分别为4.2%、8.5%、13.7%和30.1%;流式细胞仪检测显示,60nmol/L浓度PS-341处理SHI-1细胞0、6、12、24h,G1期的细胞比例分别为46.0%、30.0%、14.3%和0.8%,G2/M期的细胞比例分别为16.0%、25.5%、49.4%和69.0%。结论PS-341可以抑制SHI-1细胞生长,并能诱导其凋亡,使SHI-1细胞停留在G2/M期。 Objective To investigate inhibiting effect of proteasome inhibitor PS-341 on acute mononuclear leukemia SHI-1 cells. Methods Cultured SHI-1 cells were treated with 60 nmol/L of PS-341 for 0, 6, 12 and 24 h. Trypan blue exclusion assays was used to detect the cellular viabilities, FACS with Annexin-V staining was used to analyze cell apoptosis and cell cycle. Results PS-341 inhibited SHI-1 cells in a time- and dose-dependently manner. After PS-341 treatment for 0, 6, 12 and 24 h, apoptotic rates of SNI-1 cells were 4.2%, 8.5%, 13.7% and 30.1% respectively; FACS showed that G1 cells were 46.0%, 30.0%, 14.3% and 0.8% and G2/M cells were 16.0%, 25.5%, 49.4% and 69.0% respectively. Conclusion PS-341 can inhibit the proliferation of SHI-1 cells, induce apoptosis and block SHI-1 cells in G2/M stage.
出处 《浙江医学》 CAS 2008年第7期694-695,700,共3页 Zhejiang Medical Journal
基金 宁波市医学科技计划项目资助(200520)
关键词 蛋白酶体抑制剂PS-341 SHI-1细胞 细胞凋亡 细胞周期 Proteasome inhibitor PS-341 SHl-lcells Apoptosis Cell-cycle
  • 相关文献

参考文献7

二级参考文献41

  • 1周永列,吕亚萍,邱莲女,王文松,林惠君.硝普钠诱导K562细胞凋亡机制的研究[J].中国实验血液学杂志,2005,13(6):983-988. 被引量:5
  • 2薛永权 过宇.介绍一种改良的骨髓细胞染色体热变性姬姆萨R显带法[J].中华医学检验杂志,1986,9:247-247.
  • 3Drexler HG, Matsuo Y, Macleod RAF. Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research. Leuk Res,2000, 24:881-911.
  • 4Mitterbauer G, Zimmer C, Fonatseh C, et al. Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukemia by RT-PCR. Leukemia, 1999,13:1519-1524.
  • 5Nollet F, Billiet J, Selleslag D, et al. Standardization of multiplex fluorescent short tandem repeat analysis for chimerism testing. Born, Marros Transplant,2001 ,28:511-518.
  • 6Drexler HG, F6mbonne S, Matsuo Y, et al. p53 alterations in human leukemia-lymphoma cell lines: in vitroariifaet or prerequisite for cell immortalization? Leukemia,2000, 14 : 198-206.
  • 7Uphoff CC, Drexler HG. Detection of mycoplasma in leukemialymphoma cell lines using pnlymerase chain reaction. Leukemia, 2002,16: 289-293.
  • 8Drexler HG,Dirks WG, Matsuo Y, et al. False letzkemia-lymphoma cell lines: an update on over 500 cell lines, Leukemia,2003, 17:416-426.
  • 9Drexler HG, Matsuo Y. Guidelines for the charaetelization and publieatinn of human malignant hematupoietie cell lines. Leukemia,1999, 13:835-842.
  • 10Kubota K, Preislef HD, Lok MS, et al. Lack of effect of eolonystimulating activity on human mveloid leukemia cell line ( ML2 )cells, Leuk Res,1981, 5:311-320.

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部